Emcure Pharmaceuticals Ltd Q1 FY27 Results Analysis: Revenue Surges 23%, Gross Margin Compresses 340 bps

Emcure Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,580.45 Cr (+22.85% YoY) and PAT growth of +42.05% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

EMCURE delivered a strong Q1 with revenue growth of 22.85% YoY, nearly double its guided low-to-mid teens range, driven by a 34.2% surge in international business. Operating leverage was evident as employee costs grew only 4.1%. However, gross margin compressed 340 bps due to input cost inflation and mix shift, and domestic growth lagged the market.

Key Investment Insights

Key Positives

• Revenue grew 22.85% YoY to Rs.2,580.45 Cr, nearly double the guided low-to-mid teens range
• PAT attributable to owners grew 42.05% YoY to Rs.293.98 Cr
• International revenue grew 34.2% YoY, with all three regions (RoW, Europe, Canada) posting >24% growth
• EBITDA margin expanded 50 bps YoY to 19.7%
• Employee costs grew only 4.1% YoY, demonstrating operating leverage
• Adjusted PAT grew 33.8% YoY, confirming clean operating momentum

Risk Factors

• Domestic revenue grew 10.2% YoY, below IPM growth of ~12% and below management's aspiration of industry +100-200 bps
• Gross margin compressed 340 bps YoY to 58.4% due to input cost inflation (solvents +30%) and mix shift toward lower-margin international markets
• Freight cost headwinds flagged in pre-call note, though other expenses grew below revenue